Threonine-for-leucine mutation within domain M2 of the neuronal alpha(7) nicotinic receptor converts 5-hydroxytryptamine from antagonist to agonist.
about
Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discoveryGinseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptorsStructural basis of ligand recognition in 5-HT3 receptorsStructural determinants of selective alpha-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP.BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes.Some properties of human neuronal alpha 7 nicotinic acetylcholine receptors fused to the green fluorescent protein.The single-channel properties of human acetylcholine alpha 7 receptors are altered by fusing alpha 7 to the green fluorescent protein.Expression of functional neurotransmitter receptors in Xenopus oocytes after injection of human brain membranesExpression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy.Microtransplantation of membranes from cultured cells to Xenopus oocytes: a method to study neurotransmitter receptors embedded in native lipidsSelective effects of a 4-oxystilbene derivative on wild and mutant neuronal chick alpha7 nicotinic receptor.GABArho 1/GABAAalpha 1 receptor chimeras to study receptor desensitization.Human neuronal threonine-for-leucine-248 alpha 7 mutant nicotinic acetylcholine receptors are highly Ca2+ permeableSerum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromesProperties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes.Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain.The influence of allosteric modulators and transmembrane mutations on desensitisation and activation of α7 nicotinic acetylcholine receptorsCo-expression of the neuronal alpha7 and L247T alpha7 mutant subunits yields hybrid nicotinic receptors with properties of both wild-type alpha7 and alpha7 mutant homomeric receptorsBlockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac)Effects of Zn2+ on wild and mutant neuronal alpha7 nicotinic receptors.Neuronal nicotinic threonine-for-leucine 247 alpha7 mutant receptors show different gating kinetics when activated by acetylcholine or by the noncompetitive agonist 5-hydroxytryptamine.Strychnine activates neuronal alpha7 nicotinic receptors after mutations in the leucine ring and transmitter binding site domainsA single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.Discriminating between 5-HT₃A and 5-HT₃AB receptorsAmyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake.Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.Nicotinic acetylcholine receptors assembled from the alpha7 and beta3 subunits.Diversity of Nicotinic Acetylcholine Receptor Positive Allosteric Modulators Revealed by Mutagenesis and a Revised Structural Model.
P2860
Q26799689-FD72678D-16C5-4953-8169-BD5D118E9A77Q27027531-37338C21-F685-49D0-AE22-DC1D64F4999DQ27675326-5C948F14-76EA-4C9D-A2E3-F95F305BDBFCQ30477201-F05319AF-00B2-47B9-9D84-009212EE25EBQ33818453-329865E1-FF21-4531-9033-CFDE3E16DC5AQ34021316-BF959FCB-B1F3-4BB5-9396-8C097672AB31Q34021334-2C4ABB6F-8F97-464E-92D0-466CAAB5FD0DQ34192342-2605105A-C906-462E-978E-DDE67A4F9C1BQ34381258-590A98D9-EAF7-4FC9-B0DC-0E8DA3A41459Q34809010-F641B3BF-ACF0-4F1B-A496-3EA6759FD32FQ35028391-EA7FC0E7-7B1C-4FB1-94F0-4FD0BE233DEBQ35116467-0BC7D810-4684-4922-BC24-228BB5C548BBQ35119676-AF587FCD-648E-4A0F-97CF-6E04CA7A4E5EQ35623707-0FF5EAC5-D06B-49BB-AB89-571179A12656Q35669831-63639456-0EBC-4A7D-BD1A-B146BD078C60Q35971812-3B4323BF-056D-442C-A354-DB045834F460Q35993539-240E48DF-341C-4DA3-98C4-0052C24B9961Q35998842-8351A4BA-D605-4483-94FA-BE69837563FFQ36031349-30D54B17-E80E-46BB-97FC-BEB6E8A83D50Q36290537-4784677E-BE97-427B-B29E-C120E350B7B6Q36578906-ECF7F74D-A5EA-4843-841F-CB3CD8682E29Q36676165-C04BD9E0-C912-4194-91EF-058D3C024F45Q37327405-B59F3CAB-D269-4456-83F2-36B771CCECC3Q38089188-D02603CD-4958-42FA-955A-A56818027D66Q40673378-8A0322D9-231C-4881-BDAA-D229EA4ABE28Q43722405-19EFA3C9-EA02-4918-A0B4-24512CDAB951Q47135096-76E52E6A-FBDC-4765-A3B5-3E0FA3F09D4AQ48915237-20E0B11D-DA49-448E-AF5F-FA31FE348354Q49355412-A69FA70F-BECD-40E9-9D5B-05D58274DB8C
P2860
Threonine-for-leucine mutation within domain M2 of the neuronal alpha(7) nicotinic receptor converts 5-hydroxytryptamine from antagonist to agonist.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Threonine-for-leucine mutation within domain M2 of the neuronal alpha
@nl
Threonine-for-leucine mutation ...... ne from antagonist to agonist.
@en
type
label
Threonine-for-leucine mutation within domain M2 of the neuronal alpha
@nl
Threonine-for-leucine mutation ...... ne from antagonist to agonist.
@en
prefLabel
Threonine-for-leucine mutation within domain M2 of the neuronal alpha
@nl
Threonine-for-leucine mutation ...... ne from antagonist to agonist.
@en
P2093
P2860
P356
P1476
Threonine-for-leucine mutation ...... ine from antagonist to agonist
@en
P2093
P2860
P304
11231-11235
P356
10.1073/PNAS.93.20.11231
P407
P577
1996-10-01T00:00:00Z